The study, published in Molecular & Cellular Proteomics, used vaginal samples from mice with ovarian tumors to find molecular “fingerprints” or microenvironments of cancer. The tests identified a potential biomarker, enzyme cystatin A, which was previously associated with the immune system’s response to cancer.
The study also used tampons worn by women the day before gynecologic surgery and found cystatin A levels were twice as high in women diagnosed with ovarian cancer, compared with those of women whose samples were diagnosed as benign.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
